InMed Pharmaceuticals

9 days ago
bookmarkBookmark

InMed Pharmaceuticals is a company. It is in Vancouver, Canada and it has a male CEO called Eric A. Adams. It was founded in 1981 and is part of the Health Care sector, specifically in the Biotechnology industry.

Key facts

plus See more facts
link LinkedIn
link X (Twitter): 2K followers


Extract data

Download datasets about InMed Pharmaceuticals:

dataset Dataset of stocks from InMed Pharmaceuticals:

InMed Pharmaceuticals is one of the companies in Biotechnology, companies in Health Care, companies in Vancouver, companies in Canada and 3,456,835 companies in our database.

Talking Points

  • InMed PharmaceuticalsSmall Molecule Therapeutics
  • InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline includes programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with its subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs.
  • A global leader in the research, development and manufacturing of #rarecannabinoids. Our subsidiary @BayMedica NASDAQ: $INM #cannabinoids
  • Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based ...
  • InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Related

Connected or similar to InMed Pharmaceuticals: .

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.